ERBB2 and breast carcinoma: We have developed new polyphenolic anti-FASN compounds that exhibit in vitro and in vivo anticancer activity improving the antitumor efficacy and the toxic effects of classical FASN inhibitors, in HER2+ breast cancer cells and mouse models [19, 28, 29].